Serologic antiglycan antibodies in inflammatory bowel disease.
At diagnosis, the clinical presentation of both entities of inflammatory bowel disease (IBD), Crohn's disease (CD) and ulcerative colitis (UC), can be highly heterogeneous, leading to a delay in correct identification or differentiation between CD and UC in a subgroup of patients. In addition, the natural history of IBD patients is strikingly variable. During the life of a CD patient, in the majority of instances, stricturing or perforating complications occur, leading to surgery. Serologic antiglycan antibodies directed against various microbial carbohydrate epitopes are useful in differentiation of CD vs. UC and are a promising tool for identification of CD patients at risk for rapid progression and need for surgical intervention. Instruments for prediction of CD behavior are critical, as the use of immunomodulators and/or biologicals early in the disease course might be justified for patients with a high hazard for complicated disease behavior.
1st Department of Medicine, Semmelweis University, Budapest, Hungary.
Peter Laszlo
PL
Lakatos
Maria
M
Papp
Florian
F
Rieder
D000906:Antibodies / Q000097:blood*; D015415:Biomarkers / Q000097:blood; D003093:Colitis, Ulcerative / Q000175:diagnosis / Q000276:immunology; D003424:Crohn Disease / Q000175:diagnosis / Q000276:immunology; D006801:Humans; D015212:Inflammatory Bowel Diseases / Q000175:diagnosis* / Q000276:immunology*; D010641:Phenotype; D011134:Polysaccharides / Q000276:immunology*; D011237:Predictive Value of Tests; D011379:Prognosis
D000906:Antibodies; D015415:Biomarkers; D011134:Polysaccharides